SXSW 2019
Preventing the Cambridge Analytica of Health Data
Description:
In the future, your medical prognosis may be predicted by data from fitness monitors, genetic testing kits, insurance databases, web searches, or even your cell phone’s GPS. Want to participate in a clinical trial? No need to visit the doctor’s office, just click “I agree,” and you’re enrolled! Taking healthcare digital is exciting — it has the potential to expand beyond the academic medical center and the traditional clinical trial. It can also democratize research by making studies more accessible to underserved and remote communities, making data more diverse and inclusive. But as we freely share our information, and as tech companies edge into the healthcare sphere, what protections are needed for ourselves, and our data?
Related Media
Other Resources / Information
Takeaways
- What are the promises of big data in healthcare, where medical prognoses may be derived from fitness monitors, DNA tests, or even a cellphone’s GPS?
- How do we best tackle issues of ownership, privacy, and third party data access as we leap into this new digital age in healthcare?
- As tech companies fast become healthcare companies, disrupting the traditional R&D model, what new regulations are required to protect patients?
Speakers
- Brooke Grindlinger, Chief Scientific Officer, The New York Academy of Sciences
- Jessica Mega, Chief Medical and Scientific Officer, Verily Life Sciences
- Regina James, Vice President of Clinical Research, 2M Research
- Jennifer Miller, Assistant Professor, Yale University School of Medicine
Organizer
Brooke Grindlinger, Chief Scientific Officer, The New York Academy of Sciences
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments